Clinical StudiesWildtype p53-specific Antibody and T-Cell Responses in Cancer PatientsPedersen, Anders Elm*; Stryhn, Anette*; Justesen, Sune*; Harndahl, Mikkel*; Rasmussen, Susanne*; Donskov, Frede†; Claesson, Mogens H.*; Pedersen, Johannes W.‡; Wandall, Hans H.‡; Svane, Inge Marie§; Buus, Søren*Author Information *Department of International Health, Immunology and Microbiology ‡Department of Cellular and Molecular Medicine, The Panum Institute, University of Copenhagen §Department of Hematology, Copenhagen University Hospital, Center for Cancer Immune Therapy (CCIT), Herlev †Department of Oncology, Aarhus University Hospital, Aarhus, Denmark Anders Elm Pedersen and Søren Buus contributed equally as senior authors. Reprints: Anders Elm Pedersen, Department of International Health, Immunology and Microbiology, The Panum Institute, University of Copenhagen, Copenhagen, Denmark (e-mail: firstname.lastname@example.org). Supplemental Digital Content is available for this study. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this study on the journal's Website, www.immunotherapy-journal.com. Received January 20, 2011 Accepted June 7, 2011 Journal of Immunotherapy: November-December 2011 - Volume 34 - Issue 9 - p 629-640 doi: 10.1097/CJI.0b013e3182281381 Buy SDC Metrics AbstractIn Brief Mutation in the p53 gene based on single amino acid substitutions is a frequent event in human cancer. Accumulated mutant p53 protein is released to antigen presenting cells of the immune system and anti-p53 immune responses even against wt p53 is induced and observed in a number of human cancer patients. Detection of antibodies against wt p53 protein has been used as a diagnostic and prognostic marker and discovery of new T-cell epitopes has enabled design of cancer vaccination protocols with promising results. Here, we identified wt p53-specific antibodies in various cancer patients and identified a broad range of responses against wt p53 protein and 15-mer peptides using a novel print array technology. Likewise, using bioinformatic tools in silico, we identified CD8+ T-cell specificity or reactivity against HLA-A*02:01 binding peptides wt p53(65–73), wt p53(187–197), and wt p53(264–272) in breast cancer patients and against HLA-A*01:01 binding peptide wt p53(226–234) and HLA-B*07:02 binding peptide wt p53(74–82) in renal cell cancer and breast cancer patients, respectively. Finally, we analyzed antibody and T-cell responses against wt p53 15-mer peptides in patients with metastatic renal cell carcinoma who were alive with no evidence of disease after a follow-up period of minimum 5 years after treatment with IL-2±IFN-α±histamine containing immunotherapy to identify novel epitopes for use in immunotherapy and for potential response biomarkers. However, none of the wt p53 reactivity observed justified use of 15-mer or was related to survival in this rare patient population. Supplemental Digital Content is available in the text. © 2011 Lippincott Williams & Wilkins, Inc.